vs

Side-by-side financial comparison of KAISER ALUMINUM CORP (KALU) and Pediatrix Medical Group, Inc. (MD). Click either name above to swap in a different company.

KAISER ALUMINUM CORP is the larger business by last-quarter revenue ($929.0M vs $493.8M, roughly 1.9× Pediatrix Medical Group, Inc.). Pediatrix Medical Group, Inc. runs the higher net margin — 6.8% vs 3.0%, a 3.8% gap on every dollar of revenue. On growth, KAISER ALUMINUM CORP posted the faster year-over-year revenue change (21.4% vs -1.7%). Over the past eight quarters, KAISER ALUMINUM CORP's revenue compounded faster (12.2% CAGR vs -0.1%).

Kaiser Aluminum Corporation is an American aluminum producer. It is a spinoff from Kaiser Aluminum and Chemicals Corporation, which came to be when common stock was offered in Permanente Metals Corporation and Permanente Metals Corporation's name was changed to Kaiser Aluminum and Chemicals Corporation.

Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.

KALU vs MD — Head-to-Head

Bigger by revenue
KALU
KALU
1.9× larger
KALU
$929.0M
$493.8M
MD
Growing faster (revenue YoY)
KALU
KALU
+23.1% gap
KALU
21.4%
-1.7%
MD
Higher net margin
MD
MD
3.8% more per $
MD
6.8%
3.0%
KALU
Faster 2-yr revenue CAGR
KALU
KALU
Annualised
KALU
12.2%
-0.1%
MD

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
KALU
KALU
MD
MD
Revenue
$929.0M
$493.8M
Net Profit
$28.2M
$33.7M
Gross Margin
13.3%
Operating Margin
6.5%
9.9%
Net Margin
3.0%
6.8%
Revenue YoY
21.4%
-1.7%
Net Profit YoY
42.4%
10.5%
EPS (diluted)
$1.67
$0.40

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
KALU
KALU
MD
MD
Q4 25
$929.0M
$493.8M
Q3 25
$843.5M
$492.9M
Q2 25
$823.1M
$468.8M
Q1 25
$777.4M
$458.4M
Q4 24
$765.4M
$502.4M
Q3 24
$747.7M
$511.2M
Q2 24
$773.4M
$504.3M
Q1 24
$737.5M
$495.1M
Net Profit
KALU
KALU
MD
MD
Q4 25
$28.2M
$33.7M
Q3 25
$39.5M
$71.7M
Q2 25
$23.2M
$39.3M
Q1 25
$21.6M
$20.7M
Q4 24
$19.8M
$30.5M
Q3 24
$8.8M
$19.4M
Q2 24
$18.9M
$-153.0M
Q1 24
$18.2M
$4.0M
Gross Margin
KALU
KALU
MD
MD
Q4 25
13.3%
Q3 25
13.6%
Q2 25
12.2%
Q1 25
13.4%
Q4 24
12.5%
Q3 24
9.6%
Q2 24
13.4%
Q1 24
11.7%
Operating Margin
KALU
KALU
MD
MD
Q4 25
6.5%
9.9%
Q3 25
5.8%
13.8%
Q2 25
4.6%
12.8%
Q1 25
5.3%
7.0%
Q4 24
5.0%
7.8%
Q3 24
1.8%
6.6%
Q2 24
4.7%
-31.3%
Q1 24
3.3%
3.2%
Net Margin
KALU
KALU
MD
MD
Q4 25
3.0%
6.8%
Q3 25
4.7%
14.5%
Q2 25
2.8%
8.4%
Q1 25
2.8%
4.5%
Q4 24
2.6%
6.1%
Q3 24
1.2%
3.8%
Q2 24
2.4%
-30.3%
Q1 24
2.5%
0.8%
EPS (diluted)
KALU
KALU
MD
MD
Q4 25
$1.67
$0.40
Q3 25
$2.38
$0.84
Q2 25
$1.41
$0.46
Q1 25
$1.31
$0.24
Q4 24
$1.21
$0.37
Q3 24
$0.54
$0.23
Q2 24
$1.15
$-1.84
Q1 24
$1.12
$0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
KALU
KALU
MD
MD
Cash + ST InvestmentsLiquidity on hand
$7.0M
$375.2M
Total DebtLower is stronger
$570.5M
Stockholders' EquityBook value
$826.1M
$865.9M
Total Assets
$2.6B
$2.2B
Debt / EquityLower = less leverage
0.66×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
KALU
KALU
MD
MD
Q4 25
$7.0M
$375.2M
Q3 25
$17.2M
$340.1M
Q2 25
$13.1M
$224.7M
Q1 25
$21.3M
$99.0M
Q4 24
$18.4M
$229.9M
Q3 24
$45.7M
$103.8M
Q2 24
$70.4M
$19.4M
Q1 24
$101.6M
$8.0M
Total Debt
KALU
KALU
MD
MD
Q4 25
$570.5M
Q3 25
$577.2M
Q2 25
$583.9M
Q1 25
$590.5M
Q4 24
$597.1M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
KALU
KALU
MD
MD
Q4 25
$826.1M
$865.9M
Q3 25
$806.1M
$890.7M
Q2 25
$776.0M
$833.8M
Q1 25
$756.8M
$789.2M
Q4 24
$743.1M
$764.9M
Q3 24
$729.4M
$732.5M
Q2 24
$727.6M
$706.5M
Q1 24
$714.7M
$856.2M
Total Assets
KALU
KALU
MD
MD
Q4 25
$2.6B
$2.2B
Q3 25
$2.6B
$2.2B
Q2 25
$2.5B
$2.1B
Q1 25
$2.4B
$2.0B
Q4 24
$2.4B
$2.2B
Q3 24
$2.3B
$2.1B
Q2 24
$2.3B
$2.0B
Q1 24
$2.3B
$2.2B
Debt / Equity
KALU
KALU
MD
MD
Q4 25
0.66×
Q3 25
0.65×
Q2 25
0.70×
Q1 25
0.75×
Q4 24
0.78×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
KALU
KALU
MD
MD
Operating Cash FlowLast quarter
$-20.6M
$114.1M
Free Cash FlowOCF − Capex
$-51.1M
FCF MarginFCF / Revenue
-5.5%
Capex IntensityCapex / Revenue
3.3%
Cash ConversionOCF / Net Profit
-0.73×
3.39×
TTM Free Cash FlowTrailing 4 quarters
$-25.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
KALU
KALU
MD
MD
Q4 25
$-20.6M
$114.1M
Q3 25
$59.1M
$137.3M
Q2 25
$15.9M
$137.2M
Q1 25
$57.0M
$-117.5M
Q4 24
$43.4M
$133.0M
Q3 24
$34.1M
$91.8M
Q2 24
$26.3M
$107.0M
Q1 24
$63.3M
$-125.2M
Free Cash Flow
KALU
KALU
MD
MD
Q4 25
$-51.1M
Q3 25
$34.5M
Q2 25
$-27.7M
Q1 25
$18.8M
Q4 24
$-12.6M
Q3 24
$-17.0M
Q2 24
$-17.4M
Q1 24
$33.3M
FCF Margin
KALU
KALU
MD
MD
Q4 25
-5.5%
Q3 25
4.1%
Q2 25
-3.4%
Q1 25
2.4%
Q4 24
-1.6%
Q3 24
-2.3%
Q2 24
-2.2%
Q1 24
4.5%
Capex Intensity
KALU
KALU
MD
MD
Q4 25
3.3%
Q3 25
2.9%
Q2 25
5.3%
Q1 25
4.9%
Q4 24
7.3%
Q3 24
6.8%
Q2 24
5.7%
Q1 24
4.1%
Cash Conversion
KALU
KALU
MD
MD
Q4 25
-0.73×
3.39×
Q3 25
1.50×
1.91×
Q2 25
0.69×
3.49×
Q1 25
2.64×
-5.66×
Q4 24
2.19×
4.36×
Q3 24
3.88×
4.72×
Q2 24
1.39×
Q1 24
3.48×
-31.03×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

KALU
KALU

Packaging$440.6M47%
Aero Hs Products$213.0M23%
Transferred Over Time$200.2M22%
Automotive Extrusions$75.4M8%

MD
MD

Health Care Patient Service$421.6M85%
Hospitals Contracts$70.0M14%
Other$2.2M0%

Related Comparisons